Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A051902
Study Title: A Randomized Phase II Study of CHO(E)P vs CC 486 CHO(E)P vs Duvelisib CHO(E)P in Previously Untreated CD30 Negative Peripheral T Cell Lymphomas
CTO #: 103406
NCT Number: NCT04803201
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.